Blog

CAMBRIDGE, UK (2020-01-17) – ProteinLogic, the biomarker discovery and exploitation company, has attended the JP Morgan Health week in San Francisco. CEO Nicolas Huber, who represented the company, attended a number of industry events to promote the innovative diagnostic technology of the company. He held meetings with a number of potential commercial partners, who showed significant interest in supporting the company in bringing its leading TB asset to the market. The company is actively following up on all the opportunities attending this event has presented.

CAMBRIDGE, UK (2019-12-23) – ProteinLogic, the biomarker discovery and exploitation company, has been featured in GenomeWeb’s 360Dx diagnostics online, one of the leading diagnostics newsletters. The article followed interviews with ProteinLogic’s CEO, Dr Nicolas Huber, and a clinical collaborator of the company representing ProteinLogic’s study consortium, Dr Marcelo Cordeiro-Santos, as well as other experts in the field of TB diagnosis. The results stated in the article refer to ProteinLogic’s extensive clinical validation of its novel, blood-based, host immune response diagnostic for the ruling-out of Active TB disease in cohorts of varied genetic background, also from patients co-infected with HIV. The article further discusses the…

CAMBRIDGE, UK (2019-12-17) – ProteinLogic, the biomarker discovery and exploitation company, has been selected by UKRI to present at the prestigious BioSeed event. BioSeed is an early-stage life-sciences investment event, which provides a platform for only 60 innovative early-stage Life Sciences companies to present to over 100 specialist investors. The pitching session is followed by extensive one-to-one partnering as well as networking opportunities. Dr Nicolas Huber, CEO of ProteinLogic, commented: “The innovative work we have done at ProteinLogic, and its potential social impact, continuous to be recognised, both in the UK and abroad. We are particularly pleased of the continued support…

CAMBRIDGE, UK (2019-11-29) – ProteinLogic, the biomarker discovery and exploitation company, has been selected to represent the UK on the UKRI Global Business Innovation Programme (GBIP) in precision medicine on a mission to China. The GBIP is geared exclusively for Precision Medicine businesses working with technologies that enable early and accurate diagnosis to inform patient treatment, as well as the availability of targeted therapies. It aims to help innovative UK businesses develop relationships with partners in China, allowing them to gain a foothold in this market set for extensive growth. It is specifically meant to showcase the best of British…

CAMBRIDGE, UK (2019-10-21) – ProteinLogic, the biomarker discovery and exploitation company, will be presenting results of its novel ImmiPrint®-TB test at the 50th Union World Conference on Lung Health, to be held in Hyderabad, India. Our prominent clinical collaborators will be presenting their findings on the use of  ImmiPrint®-TB as an active TB disease rule-out test in high prevalence settings during the “Late-Breaker Session on TB” on Saturday the 2nd of November 2019.

CAMBRIDGE, UK (2019-08-06) – ProteinLogic, the biomarker discovery and exploitation company, is attending the 71st annual scientific meeting & clinical lab Expo of the American Association of Clinical Chemistry (AACC). Dr Nicolas Huber, CEO of ProteinLogic, commented: “The AACC meeting, with its exclusive focus on laboratory diagnostics, is the most prestigious meeting to be attending in the space. Our presence here creates new opportunities for ProteinLogic for strategic collaborations with established IVD manufacturers with an interest in our assets and platform technology. Further, it allows us to stay abreast of the current thinking and developments in the field of laboratory science.”

CAMBRIDGE, UK (2019-08-01) – ProteinLogic, the biomarker discovery and exploitation company, today announces the completion of its multi-site study on the use of its novel diagnostic technology, ImmiPrint®, for the ruling-out of Active Tuberculosis (TB) disease from a blood sample. Previously, the company had shown that its ImmiPrint  technology could achieve the requisite clinical accuracy in a significant internal study of approximately 1000 clinical samples on laboratory-grade immunoassay platforms. Under an EU Horizon 2020 grant (ADVANTAGE 666308), the company built on this work and commissioned clinical studies for the collection of further blood samples from subjects suspected of Active TB disease.…

ProteinLogic (PL), the biomarker discovery and exploitation company, has received approval for granting of its first patent in biomarkers for the diagnosis of Tuberculosis in the USA and the EU. At the same time, the company has filed a 2nd patent in the same space. This new patent allows the company to expand the applicability of its unique biomarker signatures in the diagnosis of Tuberculosis (TB), while introducing further unique combinations of biomarkers that can provide accurate information for the diagnosis of the disease. This patent was critically informed by the results generated from the completion of screening of large…

CAMBRIDGE, UK (2018-09-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Edward Gibson as Non-Executive Director. Dr Gibson holds a holds a degree in Chemistry from Bristol University, and a PhD in Biochemistry from Oxford University, where he also performed postdoctoral research. Since then, he has held a number of senior leadership roles with Bristol-Myers Squibb, focusing on commercialization and lifecycle management within the company’s oncology department, rising to becoming a member of the European oncology steering committee. He then went on to become Senior Director for New Product Strategy and EU commercialization with AVEO, as a…